Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s):  RKVTF

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.


TSXV:RKV - Post by User

Rakovina Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(433)
•••
Post by AwareInvestoron Apr 08, 2021 9:27am
218 Views
Post# 32955743

Rakovina Therapeutics Granted Patents For Drug Candidates

Rakovina Therapeutics Granted Patents For Drug Candidates
Rakovina Therapeutics has received patents as of this morning. Granted by both the European and Canadian patent offices, the patents are for “Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase”.

The patents that were granted to the company are related to the firms kt-2000 series of drug candidates. The patents cover both the composition of matter as well as the uses of the drug candidates. The k2-2000 series is being studied by the company as a novel series of DNA-damage response inhibitors, which is being targeted as a potential cancer therapy.

Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities